Heron Therapeutics (HRTX) Stock Price, Quote & News

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology

Sector: Healthcare

Phone: (858) 251-4400

Website: www.herontx.com

Address:

100 Regency Forest Drive, Suite 300, Cary, United States

Smartynow Nov. 15 at 2:05 PM

$HRTX Aponvie a mega partnership can get you at least % 10 of the market ( no other alternative out there ) and that % 10 is ( $ 200 million annual sales )

0 · Reply

Smartynow Nov. 15 at 1:41 PM

$HRTX the real deal ( no generic for it )

1 · Reply

keypatience Nov. 15 at 9:16 AM

$HRTX I think the share price will remain range-bound until Q4 numbers come out. Real growth should be seen next year.

0 · Reply

jlucer53 Nov. 14 at 10:03 PM

$HRTX aren't baker bros in this??? They have a fairly decent track record

1 · Reply

Shooter40 Nov. 14 at 8:26 PM

$HRTX Revenues from ZYN alone are worth more than the current market cap of HRTX based on current run rate and a reasonable multiple of revenues. This company is way undervalued.

0 · Reply

Shooter40 Nov. 14 at 8:17 PM

$HRTX Thanks Braddog for the October numbers. ZYN grew 62% compared to last October. APO grew 83% compared to last October. A very fine start to Q4!,

0 · Reply

CarpeDiem_ Nov. 14 at 6:10 PM

$HRTX Barry sitting right on our face. Peep his company lol

0 · Reply

Braddog Nov. 14 at 4:21 PM

$HRTX Zynrelef

6 · Reply

Braddog Nov. 14 at 4:20 PM

$HRTX Aponvie

0 · Reply

Judykay Nov. 14 at 2:56 AM

$HRTX

0 · Reply

Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 12 days ago

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Oct 29, 2025, 5:58 PM EDT - 18 days ago

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

Oct 21, 2025, 4:20 PM EDT - 26 days ago

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Aug 15, 2025, 7:45 AM EDT - 3 months ago

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

Aug 8, 2025, 3:46 PM EDT - 3 months ago

Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 7:45 AM EDT - 3 months ago

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

Aug 8, 2025, 7:45 AM EDT - 3 months ago

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

HTGC

Aug 8, 2025, 6:00 AM EDT - 3 months ago

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

Jul 28, 2025, 9:42 PM EDT - 3 months ago

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

May 7, 2025, 3:38 PM EDT - 6 months ago

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

May 6, 2025, 11:38 AM EDT - 6 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:45 AM EDT - 6 months ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 6, 2025, 7:30 AM EDT - 6 months ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Apr 28, 2025, 6:55 PM EDT - 7 months ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Apr 22, 2025, 4:05 PM EDT - 7 months ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Feb 27, 2025, 12:07 PM EST - 9 months ago

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:45 AM EST - 9 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Feb 13, 2025, 4:20 PM EST - 9 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Dec 23, 2024, 4:05 PM EST - 11 months ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Dec 4, 2024, 3:01 PM EST - 1 year ago

Relief For Heron Therapeutics After The Court Win On Cinvanti

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents

Nov 12, 2024, 11:45 AM EST - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:55 AM EST - 1 year ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Nov 4, 2024, 5:00 PM EST - 1 year ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Oct 29, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Oct 10, 2024, 4:08 PM EDT - 1 year ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Aug 9, 2024, 10:14 AM EDT - 1 year ago

Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

May 29, 2024, 8:05 AM EDT - 1 year ago

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 7, 2024, 2:38 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Apr 16, 2024, 4:24 PM EDT - 1 year ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 11, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 12, 2024, 10:35 PM EDT - 1 year ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Feb 28, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Feb 17, 2024, 1:54 AM EST - 1 year ago

Heron Therapeutics Is Out Of Survival Mode

Jan 23, 2024, 8:00 PM EST - 1 year ago

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Jan 7, 2024, 5:00 PM EST - 2 years ago

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

Dec 29, 2023, 3:14 PM EST - 2 years ago

Heron Therapeutics Gets Back On Track

Nov 30, 2023, 9:00 AM EST - 2 years ago

Why Heron Therapeutics Is A Compelling Buy Into 2024

Nov 14, 2023, 7:45 PM EST - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript

Smartynow Nov. 15 at 2:05 PM

$HRTX Aponvie a mega partnership can get you at least % 10 of the market ( no other alternative out there ) and that % 10 is ( $ 200 million annual sales )

0 · Reply

Smartynow Nov. 15 at 1:41 PM

$HRTX the real deal ( no generic for it )

1 · Reply

keypatience Nov. 15 at 9:16 AM

$HRTX I think the share price will remain range-bound until Q4 numbers come out. Real growth should be seen next year.

0 · Reply

jlucer53 Nov. 14 at 10:03 PM

$HRTX aren't baker bros in this??? They have a fairly decent track record

1 · Reply

Shooter40 Nov. 14 at 8:26 PM

$HRTX Revenues from ZYN alone are worth more than the current market cap of HRTX based on current run rate and a reasonable multiple of revenues. This company is way undervalued.

0 · Reply

Shooter40 Nov. 14 at 8:17 PM

$HRTX Thanks Braddog for the October numbers. ZYN grew 62% compared to last October. APO grew 83% compared to last October. A very fine start to Q4!,

0 · Reply

CarpeDiem_ Nov. 14 at 6:10 PM

$HRTX Barry sitting right on our face. Peep his company lol

0 · Reply

Braddog Nov. 14 at 4:21 PM

$HRTX Zynrelef

6 · Reply

Braddog Nov. 14 at 4:20 PM

$HRTX Aponvie

0 · Reply

Judykay Nov. 14 at 2:56 AM

$HRTX

0 · Reply

quegoalasoche Nov. 13 at 10:22 PM

$HRTX

0 · Reply

SpaceForceOne Nov. 13 at 4:29 PM

$HRTX Love him or hate him. BQ has doubled shareholder value over at Connect in the last 6 months. Pretty ironic.

2 · Reply

CarpeDiem_ Nov. 13 at 3:19 PM

$HRTX any news on Barry?

0 · Reply

Sdwg Nov. 13 at 1:38 PM

$HRTX forked this a long time ago, buyout is only chance to break the shorts grip...good luck to you longs

1 · Reply

chance111 Nov. 12 at 8:05 PM

$HRTX Things are so bad, I will celebrate if there is a buyout for $2 a share tomorrow. I just want the misery to end and everyone reading this should also celebrate because the misery will end for you as well.

1 · Reply

CarpeDiem_ Nov. 12 at 6:56 PM

$HRTX stick a fork in this turd

0 · Reply

Smartynow Nov. 12 at 4:48 PM

$HRTX Aponvie market potential 36 000 000 x $60

0 · Reply

Smartynow Nov. 12 at 4:43 PM

$HRTX

1 · Reply

Smartynow Nov. 12 at 4:41 PM

$HRTX

0 · Reply

CarpeDiem_ Nov. 12 at 4:41 PM

$HRTX are the rumors true that Barry is coming back ?

0 · Reply

Shooter40 Nov. 12 at 3:27 PM

$HRTX when management shows no interest in buying company shares in the open market for an extended period of time, one must conclude that the company’s prospects are poor and there is no significant upside to the share price. That is the lesson I have learned from owning this loser of a company for 5 Years.

4 · Reply

SpaceForceOne Nov. 12 at 3:04 PM

$HRTX Everyday , Heron continues to receive

1 · Reply

Market Cap	201.70M
Revenue (ttm)	144.29M
Net Income (ttm)	-13.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.41%
Debt to Equity Ratio	7.22

Volume	1,099,700
Avg Vol	1,719,804
Day's Range	N/A - N/A
Shares Out	183.36M
Stochastic %K	36%
Beta	1.30
Analysts	Strong Sell
Price Target	$4.50